Novavax has commenced administering the initial booster doses of its protein-based Covid-19 vaccine, NVX-CoV2373, in the paediatric expansion of the Phase III PREVENT-19 clinical trial. 

The trial will assess the safety and immunogenicity of a third dose of the vaccine in adolescent trial subjects of the age 12 to 17 years. The company anticipates reporting preliminary data from the trial during the second half of this year.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

All the subjects in PREVENT-19 of this age group are now eligible to receive a third booster dose of the vaccine.

The booster vaccine is similar to the active vaccine of 5μg of recombinant spike protein plus 50μg of Matrix-M adjuvant given earlier to the subjects under a two-dose series. 

Furthermore, the booster is intended to be given a minimum of five months following the administration of the active vaccine. 

Analysing the humoral immune response 28 days following booster dose administration and describing Covid-19 disease are the post-booster goals of the trial. 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Created from the genetic sequence of the SARS-CoV-2 virus’ initial strain, the vaccine has purified protein antigen.

The vaccine is formulated with the company’s saponin-based Matrix-M adjuvant and cannot replicate or cause Covid-19 infection.

Novavax Research and Development President Gregory Glenn said: “We see the ongoing need for alternative vaccine options because we are continuing to monitor spikes in Covid-19. 

“The expansion of our PREVENT-19 booster trial into the paediatric population reinforces our commitment to seek to make our vaccine available to a broader population.”

In March this year, the company reported that NVX-CoV2373 will be assessed as a booster in two clinical trials.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact